This weekend sees the start of the Society of Interventional Radiology 2015 meeting in Atlanta, Georgia. Interventional therapies company Penumbra, Inc., is using the event to debut its newest vascular embolization device, POD™.
Penumbra’s interventional therapies are used by specialist physicians to treat patients in three clinical markets: neurovascular disease, peripheral vascular disease and neurosurgery.
The company’s Peripheral Occlusion Device (POD) is a vascular embolization implant, deliverable through a high-flow microcatheter, permitting the physician to mechanically occlude distal vessels. POD’s proprietary anchor technology enables precise placement of the device at the target location at which point it quickly transitions to a soft packing segment to create a stable dense occlusion. Once the desired positioning is achieved, accurate, instant detachment ensures physician control.
Penumbra is also touting results of two clinical trials featuring its products, which will be presented at the meeting. These include the Aneurysm Coiling Efficiency (ACE) study analyzing the benefit of high packing density on the long-term outcome of peripheral embolization with the Ruby® Coil, and multicenter results of the acute limb ischemia revascularization study (PRISM) utilizing the Indigo® Thromboembolectomy System.
“POD is a significant advancement for vascular embolization,” said Adam Elsesser, chairman and chief executive officer of Penumbra. “Its unique design enables POD to anchor to the vessel wall, enabling interventionalists to increase accuracy and packing density during embolization procedures. Increased packing density helps ensure more effective embolization.”
Source: Penumbra, Inc.